Cytochrome P-450 3A: Interactions with dermatologic therapies - 11/05/12
Abstract |
Recent case reports and studies suggest that interactions involving the cytochrome P-450 mixed function oxidase system are important causes of medication toxicity and de-creased efficacy during combination drug therapy. The cytochrome P-450 3A3/4 isoenzyme is involved in many significant drug interactions. New and familiar drugs continue to be implicated as having potentially serious interactions with this group of enzymes. An understanding of the basic principles of these interactions may have a major impact on patient outcome. (J Am Acad Dermatol 1997;37:765-71.)
Le texte complet de cet article est disponible en PDF.Plan
Reprint requests: N. H. Shear, MD, FRCPC, FACP, Sunnybrook Health Science Centre, Department of Clinical Pharmacology, E-240, 2075 Bayview Ave., Toronto, Ontario, Canada M4N 3M5. |
|
0190-9622/97/$5.00 + 0 16/1/83475 |
Vol 37 - N° 5P1
P. 765-771 - novembre 1997 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?